Inicio・Lista de Acciones・Ardelyx Inc

Ardelyx Inc

Cerrado

SectorSanidad

5.04 0.6

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.98

Máximo

5.11

Métricas clave
By Trading Economics
Ingresos	-37M -38M
Ventas	-31M 94M
BPA	-0.15
Margen de beneficios	-39.805
Empleados	489
EBITDA	-40M -30M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+217.68% upside

Dividendos
By Acuity
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-212M 1.3B
Apertura anterior	4.44
Cierre anterior	5.04

Noticias sobre sentimiento de mercado

By Acuity

11%

89%

11 / 340 Clasificación en Healthcare

Ardelyx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 jul 2026, 19:02 UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Comparación entre iguales

Cambio de precio

Ardelyx Inc previsión

Precio Objetivo

By TipRanks

217.68% repunte

Estimación a 12 Meses

Media 16.17 USD 217.68%

Máximo 19 USD

Mínimo 13 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ardelyx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Ardelyx Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

11 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.